Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NY: DNA )

12.65 +1.07 (+9.24%)
Streaming Delayed Price Updated: 10:51 AM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ginkgo Bioworks Holdings, Inc. Class A Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
3 Key Biotech Trends for 2023 And Beyond
New opportunities are becoming apparent, but so are fresh risks in the biotech field. 
Via The Motley Fool
Ginkgo Bioworks Q1 Sales Beat Expectations, But Analyst Downgrades Stock On Guidance Concerns
Ginkgo Bioworks Holdings Inc (NYSE: DNA) reported Q1 sales of $80.70 million, beating the consensus of $71.68 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2023
Via Benzinga
Disney, Sonos, Desktop Metal And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Sonos, Inc. (NASDAQ: SONO) shares dipped 25.2% to $15.82 in pre-market... 
Via Benzinga
Ginkgo Bioworks Holdings: Q1 Earnings Insights
Via Benzinga
Earnings Preview: Ginkgo Bioworks Holdings
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
After-Hours Action: Why Ginkgo Bioworks Stock Is Sliding
Shares of cell programming platform company Ginkgo Bioworks Holdings Inc (NYSE: DNA) are moving lower after hours on the heels of a wider-than-expected quarterly loss.&nbs 
Via Benzinga
DNA Stock Earnings: Ginkgo Bioworks Misses EPS, Beats Revenue Estimates
DNA stock earnings show Ginkgo Bioworks missing analyst estimates for its loss per share but beating revenue estimates. 
Via InvestorPlace
Down 76% From Its High, Can Ginkgo Bioworks Stock Turn Things Around?
Ginkgo is coming off a strong performance in 2022, but this year will no doubt be a more challenging one for the business. 
Via The Motley Fool
7 Best Cathie Wood Stocks for Your May 2023 Buy List
This year promises to be very different for Cathie Wood stocks, as signs of economic improvement become more prominent. 
Via InvestorPlace
Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock
Wood is betting that Ginkgo Bioworks' biofoundry can scale up enough to become profitable. 
Via The Motley Fool
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries
Evogene employs an artificial intelligence platform for decoding plant phenotypes and microbial genomes. Consider its' research agenda, applications, and at-the-market products. The set-up may present... 
Via Talk Markets
Ginkgo Bioworks Holdings's Earnings: A Preview
Via Benzinga
Is It Too Early to Invest in Ginkgo Bioworks?
Ginkgo is on track to easily beat its guidance for 2022. But what about its bottom line? 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The growth-focused money manager is making moves. 
Via The Motley Fool
Cathie Wood Bets Big On Roblox With $19.5M Purchase — Also Loads Up On This Biotech Stock
Via Benzinga
5 Penny Stocks With Explosive 5X Potential
Penny stocks are inherently risky, but investing in low-priced companies with wide "moats" can shift the odds in investors' favor. 
Via InvestorPlace
3 Growth Stocks to Buy for 100% Returns
These three growth stocks to buy could provide triple-digit percentage returns for investors in the near to mid term. 
Via InvestorPlace
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
Via Benzinga
This Growth Stock Is Down 63% in 1 Year. Here's Why You Should Buy the Dip and Hold It for 5 Years
The bear market hasn't been kind, but the future could be a lot better. 
Via The Motley Fool
Luminar Technologies, EHang Holdings And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Evogene Offers An Excellent Risk/Reward Ratio
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their... 
Via Talk Markets
7 Penny Stocks With Massive Growth Potential
If you laugh at red ink, these tempting ideas just might be for you. 
Via InvestorPlace
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Buy the Dip: 2 Exceptional Growth Stocks to Grab Before the Next Bull Market
Now's the time to load up on stocks that got dented in the bear market. 
Via The Motley Fool
This Biotech Is Already Using AI, but Is the Growth Stock a Buy?
Few biotechs can claim to be using AI in as central of a role as Ginkgo Bioworks. 
Via The Motley Fool
2 Bruised Growth Stocks to Buy While They're Cheap
Both are on the verge of fast growth, and they haven't had any major setbacks yet. 
Via The Motley Fool
The Next Big Disruptors? 3 Biotech Stocks Making Headlines.
Biotech stocks were hard-hit in 2022, but these disruptive names in the field of synthetic biology can be big winners in 2023. 
Via InvestorPlace
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
These stocks are risky. But they just might deliver huge gains if analysts are right. 
Via The Motley Fool
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.